FIGURE 7.
Schematic model of how NLRC5 loss leads to reduced antigenicity and host immune evasion. Genetic and epigenetic aberrations in NLRC5 diminish MHC‐I surface expression. The subsequent reduction in antigen‐presentation impairs CD8+ T‐cell activation. These changes result in an impaired ability to elicit antitumour CD8+ T‐cell responses and reduced CD8+ T‐cell infiltration in cancer tissues.